TSX : CRDL.TO

Cardiol Therapeutics Inc.

$1.8 CAD

-$0.02 (-1.1%)

Volume
12.3K
Average Volume
66.99K
Market Capitalization
$207.49M
P/E Ratio
-4.60
Dividend Yield
0.00%
Price Target
Year High
$2.33
Year Low
$1.23
Day High
—
Day Low
—
Payout Ratio
$0.00
Current Ratio
$4.39
Company Overview

TSX

David G. Elsley

Drug Manufacturers - Specialty & Generic

Healthcare

CRDL.TO

18

CA

CAD

https://www.cardiolrx.com

289 910 0850

14161Y200

N/A

Liquidity Metrics

0.00

4.39

4.39

3.88

0.00

Sales & Valuation

-$

0.00

8.11

-8.55

-0.22

Profitability

-$0.39

-$33.82M

0.00%

0.00%

-229.16%

-115.74%

P/E Metrics

-4.60

-0.22

-0.22

Analyst Price Target & Rating

Sell

2/5

3 Analysts

%

Financial Health Scores

4.70

2/9

$24.14M

$31.41M

$7.2M

-$35.38M

Key Metrics (TTM)

No key metrics data available.

Company Executives
Name Title
Andrew Warwick Hamer Chief Medical Officer and Head of Research & Development
David G. Elsley President, Chief Executive Officer & Director
Bernard Lim Chief Operating Officer
John A. Geddes BSCPT Vice President of Corporate Development
Christopher J. Waddick Chief Financial Officer, Corporate Secretary & Director
Trevor Burns Investor Relations
Poll Results

No votes yet today — be the first to share your view!

About Cardiol Therapeutics Inc. (TSX:CRDL.TO) Stock

Cardiol Therapeutics Inc. operates as a clinical-stage life sciences company, primarily engaged in the discovery and advancement of treatments designed to combat fibrosis and inflammation within the context of cardiovascular diseases. Its flagship product, CardiolRx, is currently undergoing a significant Phase II/III international clinical trial. This extensive study is randomized, double-blind, and placebo-controlled, evaluating CardiolRx's efficacy and safety as a heart-protective therapy to mitigate cardiovascular and respiratory issues in individuals hospitalized with COVID-19. Concurrently, the trial also assesses CardiolRx's role in addressing acute myocarditis. Beyond this, the company is developing an injectable, subcutaneous formulation of CardiolRx, intended to target cardiac sca ... rring and inflammation that contribute to the development and worsening of heart failure. Established in 2017, Cardiol Therapeutics Inc. is based in Oakville, Canada.

Frequently Asked Questions

What is the current Cardiol Therapeutics Inc. (CRDL.TO) stock price?

Cardiol Therapeutics Inc.(TSX:CRDL.TO) stock price is $1.8 in the last trading session. During the trading session, CRDL.TO stock reached the peak price of $2.33 while $1.225 was the lowest point it dropped to. The percentage change in CRDL.TO stock occurred in the recent session was --1.1% while the dollar amount for the price change in CRDL.TO stock was -$0.02.

CRDL.TO's industry and sector of operation?

The TSX listed CRDL.TO is part of Drug Manufacturers - Specialty & Generic industry that operates in the broader Healthcare sector.

Who are the executives of CRDL.TO?

Andrew Warwick Hamer | Chief Medical Officer and Head of Research & Development
David G. Elsley | President, Chief Executive Officer & Director
Bernard Lim | Chief Operating Officer
John A. Geddes BSCPT | Vice President of Corporate Development
Christopher J. Waddick | Chief Financial Officer, Corporate Secretary & Director

How many employees does CRDL.TO have?

Number of CRDL.TO employees currently stands at 18. CRDL.TO operates from 2265 Upper Middle Road East, Oakville, ON L6H 0G5, CA.

Link for CRDL.TO official website?

Official Website of CRDL.TO is: https://www.cardiolrx.com

How do I contact CRDL.TO?

CRDL.TO could be contacted at phone #289 910 0850 and can also be accessed through its website. CRDL.TO operates from 2265 Upper Middle Road East, Oakville, ON L6H 0G5, CA.

How many shares of CRDL.TO are traded daily?

The average number of CRDL.TO shares traded daily for last 3 months was 66.99K.

What is the market cap of CRDL.TO currently?

The market value of CRDL.TO currently stands at $207.49M with its latest stock price at $1.8